SCHEDULE 13G: Great Point Partners and Affiliates Disclose 7.42% Stake in Inventiva S.A.

Great Point Partners, LLC, along with Dr. Jeffrey R. Jay and Ms. Lillian Nordahl, have jointly disclosed a beneficial ownership of 7.42% in Inventiva S.A., totaling 10,576,827 ordinary shares.

Summary

• Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl have filed a Schedule 13G, reporting their beneficial ownership in Inventiva S.A.
• The reporting persons collectively beneficially own 10,576,827 ordinary shares of Inventiva S.A., representing 7.42% of the company's outstanding shares.
• This ownership includes shares held by Biomedical Value Fund, L.P. (BVF) and Biomedical Offshore Value Fund, Ltd. (BOVF), where Dr. Jay and Ms. Nordahl have voting and investment power.
• BVF is the record holder of 4,853,356 shares (3.41%) and warrants to purchase an additional 2,166,666 shares (1.52%).
• BOVF is the record holder of 2,390,139 shares (1.68%) and warrants to purchase an additional 1,166,666 shares (0.82%).
• The total beneficial ownership includes 7,407,406 shares held outright and 3,333,332 shares issuable upon the exercise of warrants.
• The percentage of class is based on 139,151,274 shares outstanding as reported by Inventiva S.A. in its Form 6-K on May 5, 2025, plus the 3,333,332 shares issuable from warrants held by the reporting persons.
• The reporting persons have entered into a Joint Filing Agreement dated June 20, 2025, to file this statement jointly.
• Great Point, Dr. Jay, and Ms. Nordahl disclaim beneficial ownership of the BVF and BOVF shares, except to the extent of their respective pecuniary interests.
• The securities were not acquired and are not held for the purpose of changing or influencing the control of Inventiva S.A.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain subjective language or performance metrics that would indicate a strong positive or negative sentiment. It is neutral in tone, as expected for a Schedule 13G.

Positives

• A significant institutional investor, Great Point Partners, along with key individuals, has disclosed a substantial stake, potentially signaling confidence in Inventiva S.A.'s long-term prospects.
• The filing indicates a passive investment intent, stating the shares were not acquired for the purpose of changing or influencing control, which can be viewed positively by current management.

Negatives

• NA

Risks

• NA

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding Inventiva S.A.'s future performance or strategic direction.

Industry Context

The disclosure of a significant stake by an investment firm like Great Point Partners in a biotechnology company such as Inventiva S.A. is a common occurrence in the life sciences sector, where specialized funds often take positions in companies with promising drug pipelines or technologies. This type of filing provides transparency regarding major shareholder positions, which is crucial for market participants tracking institutional interest in the industry.

Related Party Transactions

• The reporting persons, Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl, have entered into a Joint Filing Agreement to file this Schedule 13G jointly, indicating a coordinated approach to their investment disclosure.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and potentially signal confidence.
• Management: Awareness of a large, passive shareholder, which typically does not seek to influence control, allowing management to focus on operational strategies.

Next Steps

• The reporting persons will be required to file amendments to this Schedule 13G if there are material changes to their beneficial ownership or intent, as per SEC regulations.

Key Dates

Keywords

Inventiva S.A., Great Point Partners, Schedule 13G, Beneficial Ownership, Ordinary Shares, SEC Filing, Institutional Investment, Biotechnology, Pharmaceuticals, Investment Management